Printer Friendly

NORTH AMERICAN BIOLOGICALS, INC. ANNOUNCES THIRD QUARTER AND YEAR-END 1992 OUTLOOK

 NORTH AMERICAN BIOLOGICALS, INC.
 ANNOUNCES THIRD QUARTER AND YEAR-END 1992 OUTLOOK

 MIAMI, Oct. 21 /PRNewswire/ -- North American Biologicals, Inc. ("NABI") (NASDAQ: NBIO) today announced its outlook for operating performance for the third quarter and balance of fiscal 1992.
 While final results for the three months ended Sept. 30, 1992 are not yet available, the company expects to report revenues of approximately $21.5 million for the period, up approximately 27 percent from the comparable quarter last year. The increase in sales reflects billings to customers for new FDA- and industry-mandated testing procedures, and revenue from collection centers acquired by NABI during 1992.
 The company expects to report a net loss of approximately $1 million for the quarter. This loss is primarily attributable to the increased cost of collecting plasma. Additional stringent regulatory and industry requirements have reduced the donor population pool, an industry-wide problem which the company has been addressing through a number of steps used to attract donors and increase plasma collection. The cost of these efforts, together with increases in other variable costs and the impact of allocating fixed costs across a diminished donor pool, have adversely affected the company's operating results. These results also include $1 million for the quarter in interest and amortization expense, largely associated with the company's recapitalization efforts completed in March 1992. NABI also noted that almost all of its plasma is currently sold to customers under fixed price agreements negotiated in late 1991. Most of these agreements have been re-negotiated with improved pricing for 1993.
 In commenting on the anticipated results, David Gury, NABI's chairman, president and CEO, said: "In my 30 years in the plasma industry, I have never witnessed a demand for plasma as strong as this year. In response, NABI has acquired additional collection centers and is collecting record amounts of plasma. Because industry conditions will continue to present operating challenges, our task is to continue to expand plasma collection in a cost-effective manner. We have already implemented several programs to achieve this objective, and looking ahead to 1993, we expect to see the benefits of this year's activities. In addition, next year's results will include sales of H-BIG(R), a proprietary plasma-based pharmaceutical product for Hepatitis B, recently acquired from Abbott Laboratories."
 The company expects that although fourth quarter 1992 sales will be comparable to the third quarter 1992, its results of operations will show a substantial improvement.
 North American Biologicals, Inc., headquartered in Miami, is the world's largest independent provider of human blood plasma elements to the health care industry, and has recently entered the field of proprietary, plasma-based pharmaceutical products.
 -0- 10/21/92
 /CONTACT: David J. Gury, chairman, president and chief executive officer of North American Biologicals, 305-625-5303; or Marcia A. Kean, executive vice president, or Lori Martin, account executive of Feinstein Partners, 617-577-8110, for NABI/
 (NBIO) CO: North American Biologicals, Inc. ST: Florida IN: MTC SU:


DD -- NE019 -- 3164 10/21/92 17:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 21, 1992
Words:491
Previous Article:AVONDALE SHIPYARD DIVISION AWARDED CONTRACT FOR REPAIR OF USS TRUETT
Next Article:LAUREL SAVINGS ASSOCIATION ANNOUNCES RECORD FIRST QUARTER EARNINGS
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1991 RESULTS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS SECOND QUARTER 1992 RESULTS; SALES AND OPERATING INCOME AT RECORD LEVELS FOR QUARTER AND YEAR TO DATE
ONCOGENE SCIENCE REPORTS THIRD QUARTER RESULTS
GAMMA BIOLOGICALS REPORTS EARNINGS FOR SECOND QUARTER AND SIX MONTHS
NORTH AMERICAN BIOLOGICALS REPORTS YEAR-END 1992 RESULTS
NORTH AMERICAN BIOLOGICALS, INC. REPORTS FIRST QUARTER 1993 RESULTS; RETURNS TO PROFITABILITY
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD REVENUES AND PROFITS FOR 1993
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR FIRST QUARTER 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR THIRD QUARTER AND NINE MONTHS 1994
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RESULTS FOR THIRD QUARTER AND NINE MONTHS 1995

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters